FRAZIER ALAN D
Insider CIK 1018534 · GKOS 10% owner · COLL 10% owner · CADX Director, 10% owner · ANAB 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ANAB ANAPTYSBIO INC | J Other | 2018-05-11 | 2018-05-15 | 1,372,000 | — | $0 | 973,612 | SEC↗ |
| ANAB ANAPTYSBIO INC | J Other | 2018-05-11 | 2018-05-15 | 1,372,000 | — | $0 | 973,612 | SEC↗ |
| ANAB ANAPTYSBIO INC | X Exercise deriv | 2017-02-02 | 2017-02-06 | 117,235 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | X Exercise deriv | 2017-02-02 | 2017-02-06 | 117,235 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | X Exercise | 2017-02-02 | 2017-02-06 | 117,235 | $4.55 | $533.4K | 2,345,612 | SEC↗ |
| ANAB ANAPTYSBIO INC | X Exercise | 2017-02-02 | 2017-02-06 | 117,235 | $4.55 | $533.4K | 2,345,612 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 604,055 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 195,751 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 1,428,571 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 733,740 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 209,095 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 733,740 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 195,751 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 604,055 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 1,428,571 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-01-31 | 209,095 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | P Buy | 2017-01-31 | 2017-01-31 | 311,291 | $15.00 | $4.67M | 311,291 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-01-31 | 209,095 | — | $0 | 209,095 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-01-31 | 195,751 | — | $0 | 195,751 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-01-31 | 604,055 | — | $0 | 604,055 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-01-31 | 1,428,571 | — | $0 | 1,428,571 | SEC↗ |
| ANAB ANAPTYSBIO INC | P Buy | 2017-01-31 | 2017-01-31 | 88,709 | $15.00 | $1.33M | 88,709 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-01-31 | 733,740 | — | $0 | 733,740 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-01-31 | 733,740 | — | $0 | 733,740 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-01-31 | 195,751 | — | $0 | 195,751 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-01-31 | 209,095 | — | $0 | 209,095 | SEC↗ |
| ANAB ANAPTYSBIO INC | P Buy | 2017-01-31 | 2017-01-31 | 311,291 | $15.00 | $4.67M | 311,291 | SEC↗ |
| ANAB ANAPTYSBIO INC | P Buy | 2017-01-31 | 2017-01-31 | 88,709 | $15.00 | $1.33M | 88,709 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-01-31 | 1,428,571 | — | $0 | 1,428,571 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-01-31 | 604,055 | — | $0 | 604,055 | SEC↗ |
| GKOS GLAUKOS Corp | C Conversion deriv | 2015-06-30 | 2015-06-30 | 151,653 | — | $0 | 0 | SEC↗ |
| GKOS GLAUKOS Corp | C Conversion deriv | 2015-06-30 | 2015-06-30 | 253,390 | — | $0 | 0 | SEC↗ |
| GKOS GLAUKOS Corp | C Conversion deriv | 2015-06-30 | 2015-06-30 | 1,523,809 | — | $0 | 0 | SEC↗ |
| GKOS GLAUKOS Corp | C Conversion deriv | 2015-06-30 | 2015-06-30 | 674,510 | — | $0 | 0 | SEC↗ |
| GKOS GLAUKOS Corp | C Conversion | 2015-06-30 | 2015-06-30 | 2,603,362 | — | $0 | 2,603,362 | SEC↗ |
| GKOS GLAUKOS Corp | X Exercise deriv | 2015-06-26 | 2015-06-30 | 24,705 | $7.65 | $189.0K | 674,510 | SEC↗ |
| GKOS GLAUKOS Corp | X Exercise deriv | 2015-06-26 | 2015-06-30 | 24,705 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion deriv | 2015-05-12 | 2015-05-14 | 2,705,585 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion deriv | 2015-05-12 | 2015-05-14 | 4,019,183 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion deriv | 2015-05-12 | 2015-05-14 | 3,676,078 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion deriv | 2015-05-12 | 2015-05-14 | 1,533,399 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion | 2015-05-12 | 2015-05-14 | 582,490 | — | $0 | 582,490 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | P Buy | 2015-05-12 | 2015-05-14 | 150,000 | $12.00 | $1.80M | 1,887,332 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion | 2015-05-12 | 2015-05-14 | 540,498 | — | $0 | 1,737,332 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion | 2015-05-12 | 2015-05-14 | 392,113 | — | $0 | 1,196,834 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | C Conversion | 2015-05-12 | 2015-05-14 | 222,231 | — | $0 | 804,721 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | D To issuer deriv | 2014-03-19 | 2014-03-21 | 17,500 | $11.02 | $192.8K | 0 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | D To issuer deriv | 2014-03-19 | 2014-03-21 | 25,000 | $6.79 | $169.8K | 0 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | D To issuer deriv | 2014-03-19 | 2014-03-21 | 12,500 | $4.75 | $59.4K | 0 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | D To issuer deriv | 2014-03-19 | 2014-03-21 | 12,500 | $6.84 | $85.5K | 0 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | D To issuer deriv | 2014-03-19 | 2014-03-21 | 12,500 | $4.63 | $57.9K | 0 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | D To issuer deriv | 2014-03-19 | 2014-03-21 | 12,500 | $7.65 | $95.6K | 0 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | D To issuer deriv | 2014-03-19 | 2014-03-21 | 12,500 | $1.70 | $21.3K | 0 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | D To issuer deriv | 2014-03-19 | 2014-03-21 | 15,000 | $10.80 | $162.0K | 0 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | D To issuer deriv | 2014-03-19 | 2014-03-21 | 10,000 | $12.64 | $126.4K | 0 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | U Tender | 2014-03-19 | 2014-03-21 | 4,796,711 | $14.00 | $67.15M | 0 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | U Tender | 2014-03-19 | 2014-03-21 | 3,816,474 | $14.00 | $53.43M | 0 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | M Exercise deriv | 2014-02-12 | 2014-02-21 | 1,564,129 | — | $0 | 0 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | M Exercise deriv | 2014-02-12 | 2014-02-21 | 173,792 | — | $0 | 0 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | M Exercise | 2014-02-12 | 2014-02-21 | 173,792 | $7.84 | $1.36M | 4,894,035 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | M Exercise | 2014-02-12 | 2014-02-21 | 1,564,129 | $7.84 | $12.26M | 4,692,387 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | F Tax w/h | 2014-02-12 | 2014-02-21 | 875,913 | $14.00 | $12.26M | 3,816,474 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | F Tax w/h | 2014-02-12 | 2014-02-21 | 97,324 | $14.00 | $1.36M | 4,796,711 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | A Award deriv | 2013-06-12 | 2013-06-13 | 25,000 | — | $0 | 25,000 | SEC↗ |
| CADX CADENCE PHARMACEUTICALS IN | A Award deriv | 2012-06-13 | 2012-06-14 | 17,500 | — | $0 | 17,500 | SEC↗ |